The Centralized List annual renewal application and fee must be submitted to DOJ by January 31st of each year regardless of the date of initial placement on the Centralized List. The Centralized List portion of the annual fee is $20.00 per licensee at each dealership.
Hydrocodone Bitartrate, USP 7.5 mg. Ibuprofen, USP 200 mg. VICOPROFEN (hydrocodone and ibuprofen) is supplied in a fixed combination tablet form for oral administration. VICOPROFEN (hydrocodone and ibuprofen) combines the opioid analgesic agent, hydrocodone bitartrate, with the nonsteroidal anti-inflammatory (NSAID) agent, ibuprofen.
Schedule 4 (IV) Drugs. The drug has a low potential for abuse relative to the drugs in schedule 3 The drug has a currently accepted medical use in treatment in the United States. Abuse of the drug may lead to limited physical dependence or psychological dependence relative to the drugs in schedule 3. The following drugs are listed as Schedule 4 (IV) Drugs by the Controlled Substances Act (CSA):